MORE TIME TO FOCUS ON PATIENT CARE

Reveal LINQ™ ICM System with TruRhythm™ Detection

The world’s smallest, most accurate ICM system also provides innovative ways to allow you to focus on what matters most — patient care.
MORE TIME TO FOCUS ON PATIENT CARE

Reveal LINQ™ ICM System with TruRhythm™ Detection

UNMATCHED ACCURACY
Reduce false episode review burden while maintaining high sensitivity.³

PROVEN ICM TECHNOLOGY
Continuously monitor patients for up to 3 years.¹

EXCLUSIVE SERVICES & SOLUTIONS
Designed to get you back to caring for patients.

STREAMLINE DEVICE PROGRAMMING AND INTERROGATION
Reveal LINQ™ Mobile Manager

WORLD’S SMALLEST, MOST ACCURATE ICM¹,²
Reveal LINQ ICM with TruRhythm Detection
World’s Smallest ICM\(^1\)
One-third the size of a AAA battery (1.2 cc)

World’s Most Accurate ICM Algorithm\(^2\)
TruRhythm Detection inside Reveal LINQ insertable cardiac monitor (ICM)

3-year Longevity\(^*\)
Device longevity that optimizes diagnostic yield

700+ Published Clinical Articles & Abstracts\(^4\)
Reveal™ family of ICMs

1.5T & 3T MRI Conditional
No post-insertion wait time or patient positioning restrictions\(^†\)

---

\(^*\)Reference the Reveal LINQ ICM Clinician Manual for usage parameters.
\(^1\)Reveal LINQ has demonstrated to pose no known hazards in a specified MRI environment with specified conditions of use. Please see the Reveal LINQ MRI Technical Manual for more details.
UNMATCHED ACCURACY

Reduce false episode review burden while maintaining high sensitivity.

TRURHYTHM DETECTION INSIDE REVEAL LINQ ICM

Experience Fewer False Alerts

LOWEST PUBLISHED RATE OF AF FALSE EPISODES

4.7% AF FALSE POSITIVE RATE

HIGHEST PUBLISHED AF DETECTION ACCURACY

98.9% AF DURATION SENSITIVITY

Maintain High Sensitivity

Disclaimer: A controlled, head-to-head study evaluating the comparative performance of these devices has not been done.

Based on AF episodes ≥ 2 minutes and in known AF patients. % of false positives = (1 – episode PPV). AF episodes PPV may vary between gross and patient average.

Confirm Rx™ with SharpSense™ technology & BIOMONITOR III have no published clinical evidence showing AF episode PPV or AF sensitivity. BioMonitor 2 has no published clinical evidence showing AF Sensitivity.

**Based on AF episodes ≥ 2 minutes and in known AF patients. AF sensitivity may vary between gross and patient average.
PROVEN ICM TECHNOLOGY
Continuously monitors patients for up to 3 years.*

<table>
<thead>
<tr>
<th></th>
<th>30 Days Is Not Enough</th>
<th>2 Years Is Not Enough</th>
<th>Superior Diagnostic Yield</th>
<th>Informed Treatment Decisions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cryptogenic Stroke</td>
<td><strong>88%</strong> of patients who had AF would have been missed if only monitored for 30 days**8</td>
<td><strong>30%</strong> of cryptogenic stroke AF diagnoses occur between years 2 and 3**8</td>
<td><strong>8.8x</strong> more AF detected at 36 months with ICM vs. conventional follow-up††8</td>
<td><strong>97%</strong> of patients in whom AF was detected received oral anticoagulants at 12 months**8</td>
</tr>
<tr>
<td>Syncope</td>
<td>ICM recommended for syncopal episodes &gt; 30 days apart**8</td>
<td><strong>20%</strong> of syncope diagnoses occur between years 2 and 3**11</td>
<td><strong>3.6x</strong> more likely to reach a syncope diagnosis with ICM vs. conventional care**12</td>
<td><strong>82%</strong> of Reveal™ ICM guided diagnoses led to treatment**14</td>
</tr>
<tr>
<td>Suspected AF</td>
<td><strong>84.5%</strong> of patients with AF would have been missed if only monitored for 30 days**10</td>
<td><strong>16%</strong> of patients with ICM-detected AF would be missed if monitoring stopped at 2 years**10</td>
<td><strong>4.3x</strong> more likely to reach a diagnosis with ICM in 12 months vs. one-time, 30-day monitor**13</td>
<td><strong>76%</strong> of patients with ICM-detected AF had a change in clinical management**10</td>
</tr>
</tbody>
</table>

*Reference the Reveal LINQ ICM Clinician Manual for usage parameters.
†The CRYSTAL-AF Study was a randomized, controlled study conducted on 441 patients to assess whether long-term monitoring with Reveal XT is more effective than conventional follow-up (control) for detecting atrial fibrillation in patients with cryptogenic stroke.
**Based on Kaplan-Meier estimates.
††In the CRYSTAL-AF study, the control group included 88 conventional ECGs, 20 24-hour Holters, and 1 event recorder.
***2018 ESC Guidelines for Diagnosis and Management of Syncope defined conventional testing as undefined physician discretion for monitoring excluding ICM, External Loop Recorder, Tilt Test, EP Study, Recurrent 12-lead ECG, or 7-day Holter monitor.
†††The REVEAL AF Study was a prospective, single-arm, multicenter study to quantify the incidence of AF in patients at high risk for but without previously known AF using an ICM (Reveal LINQ or Reveal XT).

**AF MANAGEMENT**

Reveal LINQ ICM provides physicians with longitudinal data to objectively determine both asymptomatic and symptomatic AF.**15,16

This data results in the measure of AF burden and accurate characterization of the AF type to effectively guide therapy decisions.**15,16
EXCLUSIVE SERVICES & SOLUTIONS

Designed to get you back to caring for patients.

STREAMLINE DEVICE PROGRAMMING AND INTERROGATION
Reveal LINQ Mobile Manager
A single, app-based solution for managing:
- Mobile convenience
- Guided workflow animations
- Integrated patient education

WORLD’S SMALLEST, MOST ACCURATE ICM
Reveal LINQ ICM with TruRhythm Detection

DIRECT SUPPORT FOR PATIENT MONITOR CONNECTIVITY ISSUES
Medtronic Stay Connected Service
A specialized patient service for monitor troubleshooting, connectivity issues, and other questions:
Direct patient line for fast service (1-866-470-7709)

EXPERT OPERATIONAL SUPPORT TO HELP MANAGE PATIENTS
Medtronic FocusOn Monitoring Service*
A remote monitoring service that helps optimize your time:
- Ensures data transmissions through patient management and communication
- Patient cardiac data review by certified technicians
- Clinically actionable reporting to inform treatment decisions

*Medtronic FocusOn Monitoring Service is provided by Medtronic Monitoring Inc., a wholly owned subsidiary of Medtronic.

CUSTOMIZE ALERTS FOR CLINICALLY ACTIONABLE REPORTS
CareLink Network
A remote monitoring network that enables data-driven care decisions:
- CareAlert notifications allow for customized reports by clinic and/or individual patient
- Cardiac Compass report provides a 90-day view of patient cardiac data
CLINICALLY ACTIONABLE REPORTS AVAILABLE ON THE CARELINK NETWORK

Event Reports
- Prioritize Critical Alerts
  - Customize to be generated daily with CareAlerts at the clinic- and/or patient-level
  - Completely optional

Full Reports
- Get the Full Picture
  - Generated when patient performs manual transmission
  - Detailed reporting of data collected since last manual transmission, including detailed episode data

Summary Reports with Cardiac Compass
- Inform Medical Treatment
  - Customize to be generated for patient diagnostic trends and to match billing cycles.

AT/AF total time per day
- This trend data is based on a count of 2-minute periods when an AT/AF episode is detected or in progress.

Ventricular rate during AT/AF
- The daily average ventricular rate is derived from the number of ventricular beats during AT/AF episodes and the total time in AT/AF for that day.

Average ventricular rate
- The average day and night heart rates are derived from the sum and number of R-R intervals during the periods defined as “day” and “night.”

Patient activity
- The sum of patient activity in hours per day.

Heart rate variability
- Median ventricular interval calculated every 5 minutes.

Clinical and patient data are fictitious and for demonstration purposes only.
World’s Smallest ICM
One-third the size of a AAA battery (1.2 cc)

World’s Most Accurate
ICM Algorithm
TruRhythm Detection inside
Reveal LINQ ICM
3-year Longevity
Device longevity that optimizes diagnostic yield

700+ Published Clinical Articles & Abstracts
Reveal family of ICMs
1.5T & 3T MRI Conditional
No post-insertion wait time or patient positioning restrictions

References

Medtronic, the Medtronic logo, and Further. Together are trademarks of Medtronic. The Bluetooth® word mark and logos are registered trademarks owned by Bluetooth SIG, Inc. and any use of such marks by Medtronic is under license.” Third party brands are trademarks of their respective owners. All other brands are trademarks of a Medtronic company.

Medtronic
710 Medtronic Parkway
Minneapolis, MN 55432-5004
USA
Toll-free in USA: 800.633.8766
Worldwide: +1.763.514.4000
medtronic.com

©2020 Medtronic. Minneapolis, MN. All Rights Reserved. Printed in USA. 02/2020